Fulcrum Therapeutics (FULC) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Fulcrum Therapeutics (FULC) over the past year, gaining 166.0% versus a loss of 60.3%. Over five years, PRLD leads with a -76.4% price change compared with -85.9% for FULC. Prelude Therapeutics is the larger company by market cap ($300.5 million vs $280.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | PRLD |
|---|---|---|
| Share price | $3.68 | $3.77 |
| Market cap | $280.77M | $300.46M |
| 1-day change | +0.27% | -1.70% |
| YTD return | -67.55% | +32.07% |
| 1-year return | -60.28% | +165.97% |
| 5-year return | -85.88% | -76.45% |
| EPS (TTM) | $-1.21 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $6.83 |
| 52-week low | $2.83 | $1.15 |
| Distance from 52-week high | -76.62% | -44.88% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -0.27% | +144.36% |
| Average volume | 1.53M | 477.45K |
| Shares outstanding | 76.30M | 65.08M |
| Employees | 9 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed FULC by 226.3 percentage points over the past year.
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
FULC vs PRLD FAQ
Which is bigger, Fulcrum Therapeutics or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $300.46M compared with $280.77M for Fulcrum Therapeutics (FULC).
Which stock has performed better over the past year, FULC or PRLD?
PRLD returned +165.97% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Fulcrum Therapeutics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.